Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Cilt numarası: 33
- Basıldığı Şehir: Illinois
- Basıldığı Ülke: Amerika Birleşik Devletleri
- Akdeniz Üniversitesi Adresli: Evet